Advertisement

Topics

Biotech’s stock goes down in flames after cannabidiol drug failure

03:46 EDT 8 Aug 2017 | Pharmafile

Zynerba Pharmaceuticals had hoped that its anti-seizure therapy could replicate the kind of success leading competitors had achieved in showing reductions in the number of seizures attained through cannabis-based products. However, it stumbled at the Phase 2 clinical stage – failing to hit any of its targets.

Zynerba’s gel is its lead clinical candidate and was being tested in adult epilepsy patients with focal seizures. The primary endpoint was the reduction of these seizures in the 188 patients involved in the study.

read more

Original Article: Biotech’s stock goes down in flames after cannabidiol drug failure

NEXT ARTICLE

More From BioPortfolio on "Biotech’s stock goes down in flames after cannabidiol drug failure"

Quick Search
Advertisement
 

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...